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In the presence of subtherapeutic drug levels, viral replication
persists, resulting in the formation of mutations and resistant
variants.3 There are various reasons for failure to suppress viral
replication to undetectable levels.4 Non-adherence is one of
the major reasons for incomplete suppression.3 Non-
adherence can be due to high pill burden, high frequency of
dosing, dietary restrictions, and lack of tolerance of adverse
effects.4
Pharmacological factors also play an important role in
treatment failure. Pharmacodynamic drug-drug interactions
can change the pharmacological effect of a drug. The
pharmacological effect of two or more drugs can act additively
or antagonistically.4 Pharmacokinetic drug-drug interactions
are associated with inappropriate plasma concentration of
drugs. Changes in plasma concentration of drugs can be the
result of inadequate absorption, inadequate transport,
inadequate metabolism, or inadequate elimination.4
Antiretroviral drugs and antibiotics used for opportunistic
infections are metabolised by various isoenzymes in the
cytochrome P450 (CYP) enzyme system, which consists of a
superfamily of haemoproteins.4 These isoenzymes catalyse the
oxidative metabolism of a wide variety of exogenous chemicals
such as therapeutic drugs, carcinogens and toxins; and
endogenous compounds such as steroids, fatty acids and
prostaglandins.5 The CYP enzyme family plays an important
role in phase 1 metabolism of these drugs.5 The biotrans-
formation of these drugs and chemicals is responsible for the
clinically significant drug interactions during multiple drug
therapy.6 Each isoenzyme of the CYP family is a specific gene
product with characteristic substrate specificity.5 Although
there are many types of isoenzymes, only six isoenzymes,
namely CYP3A4, 1A2, 2C9, 2C19, 2D6 and 2E1, are important
in the hepatic metabolism of the drugs. Many drug
interactions are the result of either induction or inhibition of
the CYP isoenzymes.7 CYP3A4 is the most predominant
isoenzyme in the liver, accounting for 30% of CYP proteins in
the liver, and metabolising 30 - 40% of drugs, including the PIs
and the NNRTIs.7 Substantial levels of CYP3A4 are also present
in the small-intestinal epithelium, and play a role in the
presystemic elimination of orally administered drugs.7
Another protein, the P-glycoprotein, plays an important role in
actual body and tissue sanctuary site penetration and this
remains important for the oral bioavailability of certain drugs.8
ENZYME INHIBITION
The majority of clinically important drug interactions are based
on inhibition of the CYP isoenzymes, thus causing a decreased
metabolism of medications. A drug may inhibit a CYP
isoenzyme whether it is a substrate of that isoenzyme or not.6
Inhibition of CYP isoenzymes causes a dose-related increase in
plasma concentration of substrate within minutes to hours of
the first dose, thus potentially causing toxicity.4 Drugs with a
long half-life and a narrow therapeutic index can potentially
cause serious side-effects.4
For the sake of completion enzyme inducers increase the
production of CYP isoenzymes, and thus accelerate the
metabolism of various medications. It is worth noting that the
antiretroviral drug efavirenz is both an inducer and an
inhibitor of CYP isoenzymes.4
RITONAVIR-BOOSTING EFFECT ON PIs
HAART regimens that include a PI have had a dramatic impact
on HIV-related morbidity and mortality. Following their
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The advent of highly active antiretroviral treatment (HAART) has had the dramatic effect of changing HIV infection from a
relentlessly progressive disease with inevitable death to a disease that is chronic and manageable. The goal of HAART is to
suppress HIV replication maximally, and thereby restore immunological function, reduce HIV-related morbidity and mortality,
and improve quality of life.1 HIV-infected persons who qualify for treatment can be treated with a HAART regimen consisting
of two nucleoside reverse transcriptase inhibitors (NRTIs) combined with a non-nucleoside reverse transcriptase inhibitor
(NNRTI) or a protease inhibitor (PI).2
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introduction into clinical practice, there has been a sharp
decline in AIDS-related deaths by 47% in the USA.9 However,
the limited bioavailability of, and lack of adherence to, PIs
because of high frequency of dosing, high pill burden, dietary
and fluid restrictions and intolerance of adverse effects, can
lead to the development of resistant strains and virological
failure.10 Any strategies that reduce the collective impact of
the adherence–limiting factors mentioned above will improve
the patient’s motivation and willingness to adhere to therapy.11
In this section the authors will limit the PI drugs to those
currently and readily available in South Africa.
Some PIs (lopinavir and saquinavir) undergo extensive first-
pass metabolism via the CYP isoenzyme system, primarily via
CYP3A4 in the liver and the small intestine.3 Of all the PIs,
ritonavir is the most potent and most effective inhibitor of
CYP3A4, and is therefore also a potent inhibitor of the
metabolism of the other PIs.3 Ritonavir also inhibits CYP3A4 in
areas of the body outside the liver and the intestinal tract.12
Co-administration (boosting) of a PI with low-dose ritonavir
(100 - 200 mg) can increase the total area under the
concentration versus time curve (AUC) of the primary PI, as
well as the minimum concentration (Cmin). The maximum
concentration (Cmax) of the primary PI is also increased,
although to a lesser extent than that for AUC and Cmin.
3
Plasma peak and trough levels of the primary PI in a boosted
PI regimen is generally higher than when the primary PI is
given without boosting with ritonavir. The antiretroviral
activity of the primary PI is consequently enhanced in terms of
intensity and duration.12 The pharmacokinetics of the different
PIs varies, as does the effect ritonavir has on their
pharmacokinetics.13
Two distinct patterns of PI boosting are seen, namely
■ the Cmax boosting effect with a modest t1/2 boosting, or
■ the t1/2 boosting with a modest AUC level boosting.
13
Table I divides the relevant PIs into Cmax and t1/2 boosting
patterns.
Saquinavir is removed by first-pass metabolism in the small
intestine, limiting its bioavailability. Ritonavir improves the
efficacy of saquinavir by inhibiting first-pass metabolism and
thereby increasing AUC, Cmin, and Cmax.
14 Indinavir has
relatively good bioavailability, but has a comparatively short
t1/2. Ritonavir improves indinavir efficacy primarily by
inhibiting hepatic metabolism, and decreasing systemic
clearance.15 This leads to larger increases in Cmin than AUC,
while having less effect on Cmax.
16 Trough indinavir levels are
maintained above the IC95.
17 The effect of ritonavir boosting
on nelfinavir pharmacokinetics is less than on other PIs, as
nelfinavir is metabolised by several CYP isoenzymes, and has
relatively good bioavailability.18 Larger increases are observed
in the AUC, Cmin and Cmax of nelfinavir’s M8 metabolite, but
the increases are generally no larger than 1-fold.13 Lopinavir is
only available in combination with ritonavir, and, like
saquinavir, benefits from ritonavir’s inhibition of first-pass
intestinal metabolism.13 Ritonavir’s effect on amprenavir
appears to be similar to its effect on indinavir, with inhibition
of hepatic metabolism leading to larger increases in Cmin than
AUC.16
Low plasma levels of PIs are strongly related to virological
failure, but it is ultimately the amount of free drug within the
HIV-infected cell, where HIV replication actually occurs, that
will most closely influence antiretroviral activity.17 Drug efflux
transporters play an important role in establishing and
maintaining HIV sanctuary sites by lowering the intracellular
drug concentrations via an efflux mechanism.18-20 P-glyco-
protein and multidrug-resistant protein (MRP) are two such
drug efflux transporters whose substrates include PIs and
NNRTIs. High levels of expression of these proteins may be
found in patients treated for HIV infection, thereby reducing
drug absorption from the intestinal tract and enhancing drug
elimination in bile and urine.20-22 P-glycoprotein and MRP
efflux transporters in the endothelial cells of the blood-brain
barrier may also prevent the transport of PIs into the central
nervous system.20,21,23 Evidence has been presented that
ritonavir inhibits functional activity of P-glycoprotein and
MRP efflux transporters, allowing a second PI to pass through
cellular boundaries.16,23-25 Thus ritonavir inhibition of efflux
transporters combined with the bioavailability of higher
plasma levels of the primary PI, appears to facilitate PI
penetration into the HIV sanctuaries.15,16,21,26 The inhibition of
P-glycoprotein and MRP by ritonavir not only helps retain PI
levels intracellularly, but also increases the oral bioavailability,
systemic exposure and central nervous system penetration of
the primary PI and ultimately decreases the secretion of the
circulating drug into the intestinal lumen.17,18,27
ADVANTAGES OF PI BOOSTING
INCREASED POTENCY AND EFFICACY
HAART regimens containing an unboosted PI result in trough
drug levels that are likely to be only slightly higher than the
50% inhibitory concentration (IC50).
3 However, boosting with
low-dose ritonavir results in primary PI trough levels becoming
substantially higher than the IC50 or IC95.
3 The addition of low-
dose ritonavir to amprenavir, fosamprenavir or indinavir
produces substantial increases in Cmin and AUC, with more
moderate or minimal increases in Cmax.
13 Low-dose ritonavir
substantially increases Cmin, Cmax and AUC of both lopinavir
and saquinavir.28 However, there is little effect on nelfinavir
pharmacokinetics.13
DECREASED RISK OF DRUG RESISTANCE
The high peak and trough levels of the primary PI that are
achieved with low-dose ritonavir boosting exceed the IC50 and
Cmax boosting t1/2 boosting
Saquinavir Amprenavir
Lopinavir Indinavir
Nelfinavir – effect unknown
TABLE I. TWO DISTINCT PATTERNS OF PI BOOSTING ARE
PRESENT AND THE PHARMACOKINETICS OF THE RELEVANT
PIs ARE DIVIDED BELOW
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IC95 so that there is a high genetic barrier against the
development of resistance. 
REGIMEN SIMPLIFICATION
PI boosting with low-dose ritonavir results in greater oral
bioavailability and longer half-life of the primary PI. Patient
adherence is promoted by less frequent dosing, a lower pill
burden, and the elimination of food and fluid restrictions.3
BOOSTED PI REGIMEN IN TREATMENT-EXPERIENCED
PATIENTS
Treatment-experienced patients can also benefit greatly from
PI boosting. In patients in whom previous regimens have
failed, adequate virological suppression afforded by PI
boosting can delay the emergence of new viral mutations that
confer further PI resistance and cross-resistance, thereby
helping to preserve future treatment options.3
DISADVANTAGES OF  PI BOOSTING
ADVERSE EFFECTS
As a result of the higher peak levels reached with PI boosting,
an increased frequency of PI-related adverse effects has been
observed.3 Indinavir-associated nephrolithiasis in PI-boosted
regimens may increase in incidence.29
Dyslipidaemia, with elevated levels of total cholesterol, low-
density lipoprotein cholesterol or triglycerides, is a PI-related
adverse effect that has to be monitored closely because of the
increased cardiovascular risk.30 Dyslipidaemia, in the form of
increased triglycerides, appears to be more severe with
ritonavir than with other PIs.31 Elevated serum lipid levels have
been observed when indinavir, lopinavir or saquanavir is
boosted with low-dose ritonavir.32-39 Gastro-intestinal side-
effects are common, especially diarrhoea. PI boosting with
ritonavir cannot be used in patients who are allergic to
ritonavir.
DRUG-DRUG INTERACTIONS
Since all the available PIs are metabolised by, and are inhibitors
of, CYP3A4, and since ritonavir is a particularly potent
inhibitor, numerous drug interactions can potentially occur
with an inducer, an inhibitor or a substrate of this isoenzyme.40
Ritonavir metabolism also involves the CYP2D6 and 1A2
isoenzymes, so that co-administration of drugs that are
metabolised by these isoenzymes may result in altered drug
activity.3
Ritonavir also inhibits, although to a lesser extent, CYP2C19,
which is important in the metabolism of nelfinavir, and the
metabolism of its active metabolite, M8.13
Further, ritonavir can induce some P450 isoenzymes and this
inhibiting effect may in some instances help to overcome
other drugs that interact by induction.13
THE FUTURE
In view of the pharmacokinetics of low-dose ritonavir-boosted
PIs with high AUC, high trough and peak levels, high Cmin,
good bioavailability, and high genetic barrier to mutations and
resistance, is it not an opportune time to have a paradigm
shift from the traditional triple therapy consisting of a
backbone of two NRTIs together with a NNRTI or a PI, to
monotherapy with low-dose ritonavir-boosted PIs such as
LPVr (Kaletra)?41
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